GLP-1 telehealth revenue rests on extrapolated ARR; FDA/Novo crackdown on compounded semaglutide knocks the public proxy down.
Iran war exposed a US autonomy gap; procurement pivots to AI-orchestrated systems, and the kill-chain software layer compounds.
Frontier-lab training spend accelerates through the decade; the compute supplier capturing those dollars gets a sustained bid.
Lilly's oral GLP-1 (non-peptide) just got approved, validating its pipeline as compounders peddle baseless oral tirzepatide.
Saudi PIF controls Lucid and forces it to build a Saudi factory for strategic, not commercial, reasons.
Agents replacing form-based SaaS guts the per-seat model, compressing legacy workflow-SaaS multiples.
U.S. naval recapitalization accelerates to close the China shipbuilding gap, and HII is the prime builder.
Daily/instant pay turning into table stakes pulls EWA through payroll incumbents, lifting Paychex attach and stickiness.